LakeShore Biopharma Co., Ltd. Income Statement

Ask AI

Financial Statements

In millions of CNY; shares in millions, except per-share amounts

	FY2025 12 months to Mar 31, 2025	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023
Revenues
Cost of revenues
Gross profit
Operating expenses:
Selling and marketing
General and administrative
Impairment loss on inventory, property, plant and equipment and other assets
Research and development
Total operating expenses
Loss from operations
Other income (expenses):
Late fees related to taxes other than income tax
Late fees related to social security insurance
Late fees for taxes other than income tax
Late fees for social security insurance
Government grants
Financial expenses
Fair value changes of warrant liability
Other income(expense)
Total other income (expense)
Loss before income taxes
Income tax benefit(expense)
Net loss
Other comprehensive income (loss), net of tax: Foreign currency translation adjustment
Total comprehensive loss
Loss per share*:
Loss per share basic (in Dollars per share and Yuan Renminbi per share)
Loss per share diluted (in Dollars per share and Yuan Renminbi per share)
Weighted average number of ordinary shares outstanding*:
Weighted average number of ordinary shares outstanding basic (in Shares)
Weighted average number of ordinary shares outstanding diluted (in Shares)
Accretion to redemption value of convertible redeemable preferred shares
Net loss attributable to Lakeshore Group
Net loss

Comments